关键词: 肺腺癌, 多发脑转移, 厄洛替尼, 放疗, 靶向药物

Abstract:

Objective To detect the clinical efficacy and safety of erlotinib combined with simultaneouswhole brain radiotherapy with simultaneous integrated boost（WBRT⁃SIB）in patients with lung adenocarcinomawith multiple cerebral metastases with EGFR mutation. Methods 45 pulmonary adenocarcinoma patients withbrain metastases，treated with erlotinib combined with WBRT⁃SIB were in combination therapy group（n = 22）andpatients treated with WBRT⁃SIB only were in radiotherapy group（n = 23）. The short⁃term effects，long⁃term effectsand adverse reactions of these two groups were compared. Results The short⁃term effective response rate（RR）ofthe combination therapy group was 77.72% ，which was significantly higher than that of the radiotherapy group（47.82%）（P < 0.05）. The one⁃year survival rate of the combination therapy group was 59.09%（13/22），whichwas significantly higher than that of the radiotherapy group 43.47%（10/23）（P < 0.05）. The main adverse reactionsin the two groups were fatigue and rash，most of which were mild，improved after symptomatic treatment，and noⅣadverse reactions. Conclusion Pulmonary adenocarcinoma patients with multiple brain metastases，have anideal clinical effect with WBRT⁃SIB combined with erlotinib. It prolongs the survival time of patients and reducesthe incidence of adverse reactions. It is worthy of promotion.

Key words: pulmonary adenocarcinoma, multiple brain metastases, erlotinib, radiotherapy, tar?geted drugs